Results 71 to 80 of about 148,376 (307)

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, EarlyView.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis

Haematologica, 2015
Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty may ...
Sajitha Sachchithanantham, Mark Offer, Christopher Venner, Shameem A. Mahmood, Darren Foard, Lisa Rannigan, Thirusha Lane, Julian D. Gillmore, Helen J. Lachmann, Philip N. Hawkins, Ashutosh D. Wechalekar   +10 more
doaj   +1 more source

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Circulation, 2019
BACKGROUND Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with
T. Lane, M. Fontana, A. Martinez-Naharro, C. Quarta, C. Whelan, A. Petrie, D. Rowczenio, J. Gilbertson, D. Hutt, T. Rezk, Svetla G Strehina, Joan Caringal-Galima, R. Manwani, F. Sharpley, A. Wechalekar, H. Lachmann, S. Mahmood, S. Sachchithanantham, E. Drage, Harvey Jenner, R. McDonald, Ottavia Bertolli, A. Calleja, P. Hawkins, J. Gillmore   +24 more
semanticscholar   +1 more source

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis

ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò, Mattia Zampieri, Carlotta Mazzoni, Carlo Fumagalli, Michela Baccini, Alessandra Mattei, Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Gianfranco Sinagra, Marco Merlo, Giacomo Tini, Beatrice Musumeci, Domitilla Russo, Pier Filippo Vianello, Marco Canepa, Roberto Licordari, Gianluca di Bella, Claudio Rapezzi, Federico Perfetto, Francesco Cappelli   +20 more
wiley   +1 more source

Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study

ESC Heart Failure
Aims Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated biomarker levels and limited thresholds for stratifying severe cardiac damage.
Amira Zaroui, Mounira Kharoubi, Romain Gounot, Silvia Oghina, Charlotte Degoutte, Melanie Bezard, Arnault Galat, Soulef Guendouz, Louise Roulin, Vincent Audard, Vincent Leroy, Emmanuel Teiger, Elsa Poullot, Valérie Molinier‐Frenkel, Fabien Le Bras, Karim Belhadj, Jean‐Philippe Bastard, Soraya Fellahi, Jason Shourick, Francois Lemonier, Thibaud Damy   +20 more
doaj   +1 more source

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis

The Journal of Pathology: Clinical Research, 2019
The tissue diagnosis of amyloidosis and confirmation of fibril protein type, which are crucial for clinical management, have traditionally relied on Congo red (CR) staining followed by immunohistochemistry (IHC) using fibril protein specific antibodies ...
Tamer Rezk, Janet A Gilbertson, P Patrizia Mangione, Dorota Rowczenio, Nigel B Rendell, Diana Canetti, Helen J Lachmann, Ashutosh D Wechalekar, Paul Bass, Philip N Hawkins, Vittorio Bellotti, Graham W Taylor, Julian D Gillmore   +12 more
doaj   +1 more source

Primary (AL) Amyloidosis Following COVID‐19 Infection: A Case Report [PDF]

Clin Case Rep
ABSTRACT Primary (AL) amyloidosis is a rare systemic disorder caused by extracellular deposition of monoclonal immunoglobulin light chains, resulting in multi‐organ dysfunction. SARS‐CoV‐2 infection may induce persistent inflammatory and immune dysregulation, potentially promoting amyloid formation, although clinical evidence is limited, making the ...
Gholami N, Tahsini Tekantapeh S, Khalaji A, Nejati B, Ravaei G.   +4 more
europepmc   +2 more sources

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure [PDF]

, 2023
Hong Yang, Rui Li, Fei Ma, Yujian Liu, Xingwei He, Qiao Yang, Dao Wen Wang, Hesong Zeng, Hong Wang   +8 more
openalex   +1 more source

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

Neurological Therapeutics, 2020
Hereditary variant transthyretin amyloidosis (ATTRv) is a rare genetic defect that affects about 5000–10,000 people worldwide, causing amyloidosis secondary to misfolding of mutant transthyretin (TTR) protein fibrils.
Ivan Urits, Daniel Swanson, Michael C Swett, Anjana Patel, Kevin Berardino, Ariunzaya Amgalan, A. Berger, Hisham Kassem, A. Kaye, Omar Viswanath   +9 more
semanticscholar   +1 more source